Results 111 to 120 of about 93,945 (299)

The bidirectional immunoregulatory effects of Traditional Chinese Medicine on the cGAS-STING signaling pathway and their translational prospects

Chinese Medicine
The cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS-STING) pathway is a central component of innate immunity, mediating host defense against pathogens, antitumor responses, and inflammation.
Yi Yang, Yiheng Sun, Yuxiang Cheng, Ziteng Pan, Jing Zhou   +4 more
doaj   +1 more source

Definitive chemoradiotherapy with Carboplatin Plus Paclitaxel for Unresectable Locally Advanced Thymic Carcinoma: A case series

Current Problems in Cancer: Case Reports
Objectives: Thymic carcinoma (TC) is rare. There is no evidence regarding the treatment strategies for unresectable locally advanced thymic carcinomas. Definitive chemoradiotherapy may treat this condition. However, an appropriate concurrent chemotherapy
Koichiro Nozaki, Satoshi Watanabe, Ryo Yamazaki, Masashi Arita, Toshiaki Kikuchi   +4 more
doaj   +1 more source

Kaplan-Meier estimates of relapse-free survival and disease-free survival for patients receiving Neoadjuvant-concurrent chemoradiotherapy versus Concurrent chemoradiotherapy versus IMRT alone.

, 2013
Kaplan-Meier estimates of relapse-free survival and disease-free survival for patients receiving Neoadjuvant-concurrent chemoradiotherapy versus Concurrent chemoradiotherapy versus IMRT alone.
Yajuan Zhou (282972), Xia Fan (282967), Xuemei Ji (282962), Desheng Hu (282965), Conghua Xie (282964), Yingjie Zheng (282977)   +5 more
core   +1 more source

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

International Journal of Cancer, EarlyView.
What's New? This study introduces a novel approach for detecting locally advanced esophageal carcinoma using cell‐free DNA (cfDNA) analysis through a highly sensitive fragmentome assay. Unlike traditional sequencing‐based methods that are limited by the absence of specific mutations in esophageal tumors, our method offers an alternative by quantifying ...
Anouchka Modesto, Sophie Gibert, Caroline Delmas, David Tougeron, Amaury Paumier, Alexandre Taillez, Samuel Le Sourd, Delphine Argo Leignel, Philippe Ronchin, Ariane Darut Jouve, Véronique Vendrely, Olivier Riou, Jérôme Martin‐Babau, Thomas Leroy, Laurent Quéro, Naïma Hanoun, Pierre Cordelier, Veronica Pezzella, Jean Pierre Delord, Rosine Guimbaud, Elizabeth Moyal, Catherine Seva   +21 more
wiley   +1 more source

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI‐SAFRADJU‐2501)

International Journal of Cancer, EarlyView.
ABSTRACT The recommended adjuvant chemotherapy (adj‐ChT) regimen for resected biliary tract cancers (BTC) is capecitabine (Cape); yet, the recommendation is based on limited evidence. Although varied adj‐ChTs have been employed in practice, robust real‐world data is scarce. We conducted a national, multicenter, hospital‐based registry study to evaluate
Erman Akkus, Mehmet Kayaalp, Müzeyyen Aslı Ergözoğlu, Ilgın Koç Kuş, Doğan Bayram, Bilgeşah Kılıçtaş, Emel Ayvaz Güneyin, Ali Kalem, Haydar Temizyürek, Mehmet Mutlu Çatlı, Mehmet Sinan Akarca, Maral Martin Mıldanoğlu, Görkem Turhan, Mahmut Kara, Hacı Arak, Feyza Arslan Tan, Burak Paçacı, Berkay Yeşilyurt, Orhun Akdoğan, Emine Bihter Çetin, Selahattin Çelik, Fatma Keskin Uzundere, Elif Şahin, Zehra Sadak Öcal, Lamia Şeker Can, Bahadır Köylü, Mehmet Cem Fidan, Esmanur Kaplan Tüzün, Teoman Şakalar, Elif Sertesen Çamöz, Haydar Çağatay Yüksel, Onur Yazdan Balçık, Pınar Peker, Mehmet Yılmaz, Şeymanur Ala Enli, Erdem Kölemen, Sibel Oyucu Orhan, Yakup Düzköprü, Mustafa Ersoy, Tuğba Akın Telli, Mesut Yılmaz, Yusuf İlhan, Atila Yıldırım, Ramazan Coşar, Müslih Ürün, Arif Hakan Önder, Murat Araz, Ertuğrul Bayram, Havva Yeşil Çınkır, Ali Alkan, Mustafa Gürbüz, Nilüfer Avcı, Fatma Paksoy Türköz, İsmail Oğuz Kara, Fatih Köse, İlkay Tuğba Ünek, Ahmet Bilici, Öznur Bal, Şuayib Yalçın, Lorenza Rimassa, Hatime Arzu Yaşar   +60 more
wiley   +1 more source

Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial

, 2012
Background The effect of the addition of adjuvant chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma is unclear.
Sun, Ying, Mao, Yan-Ping, Guo, Ying, Wei-Xiong Li, Guo-Xian Long, Zheng, Bao-Min, Ting-Ting Xu, Sun, Yan, Chao-Su Hu, Bao-Min Zheng, Ying Guo, Chen, Xiao-Zhong, Long, Guo-Xian, Guo-Qing Hu, Ying Sun, Hu, Chao-Su, Zhi-Bin Cheng, Xiao-Zhong Chen, Chen, Yong, Yu-Ming Chen, Hu, Guo-Qing, Shao-Bo Liang, Liang, Shao-Bo, Lei Chen, Meng-Zhong Liu, Yuan-Yuan Chen, Xu, Ting-Ting, Wang, Si-Yang, Chen, Lei, Yan-Ping Mao, Si-Yang Wang, Li, Wei-Xiong, Liu, Meng-Zhong, Bin Li, Xie, Fang-Yun, Cheng, Zhi-Bin, Li, Bin, Ling-Long Tang, Jun Ma, Ma, Jun, Fang-Yun Xie, Chen, Yu-Ming, Yan Sun, Chen, Yuan-Yuan, Tang, Ling-Long, Yong Chen   +45 more
core   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

Nutritional and clinical outcomes of chemoradiotherapy for clinical T1N0M0 esophageal carcinoma

Cancer Management and Research, 2019
Katsuyuki Sakanaka,1 Kota Fujii,1 Yuichi Ishida,1 Shin’ichi Miyamoto,2 Takahiro Horimatsu,3 Manabu Muto,3 Takashi Mizowaki11Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan ...
Sakanaka K, Fujii K, Ishida Y, Miyamoto S, Horimatsu T, Muto M, Mizowaki T   +6 more
doaj  

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long‐Term Survival Outcomes

International Journal of Cancer, EarlyView.
ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor, James Tankel, Pierre‐Olivier Fiset, Mehrnoush Dehghani, Nicholas Bertos, Carmen Mueller, Jonathan Cools‐Lartigue, Sophie Camilleri‐Broet, Lorenzo Ferri   +8 more
wiley   +1 more source